3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Glioblastoma
4
Glioma
3
Multiple Myeloma
2
Lymphoma
2
Astrocytoma
2
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lipodystrophy, Congenital Generalized
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hodgkin Disease
1
Gliosarcoma
1
Carcinoma
1
Advanced Fallopian Tube Carcinoma
1
Interventions
Cytarabine
358
Cyclophosphamide
241
Azacitidine
213
fludarabine phosphate
199
venetoclax
198
fludarabine
196
Busulfan
148
Decitabine
132
Mycophenolic Acid
123
Whole-Body Irradiation
122
Peripheral Blood Stem Cell Transplantation
118
Tacrolimus
115
Granulocyte Colony-Stimulating Factor
104
Idarubicin
100
Filgrastim
100
Melphalan
89
Cyclosporine
89
Methotrexate
83
Daunorubicin
76
Antilymphocyte Serum
75
Etoposide
73
Mitoxantrone
67
Clofarabine
67
Gemtuzumab
59
Stem Cell Transplantation
55
Thiotepa
51
Cladribine
46
Injections
45
Specimen Handling
44
thymoglobulin
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, Myeloid, Acute
×
Tetanus Toxoid
×
Clear all
NCT01611298
2020-04-21
TAR
Baylor College of Medicine
Phase NA
Completed
7 enrolled
8 charts